Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Northway Biotechpharma","sponsor":"Memo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG and Northway Biotechpharma Collaborate Fast-Track Manufacturing of a SARS-CoV-2-Neutralizing Antibody for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"LITHUANIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Northway Biotechpharma"}]

Northway Biotechpharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Memo Therapeutics AG and Northway Biotechpharma Collaborate Fast-Track Manufacturing of a SARS-CoV-2-Neutralizing Antibody for COVID-19

Details:

Under the terms of the agreement, Northway will develop the cell line and the manufacturing process, and will further produce cGMP batches of MTx´s antibody for clinical studies and will also execute commercial production once MTX-COVAB receives marketing authorization.

Lead Product(s): MTX-COVAB

Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-COVAB

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Memo Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 14, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY